Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) is a biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company is part of the Zacks Medical - Drugs industry. On November 4, 2025, RBC Capital set a price target of $15 for AUPH, while the stock was trading at $14.27, indicating a potential upside of approximately 5.12%.
During its Q3 2025 earnings call, Aurinia reported earnings of $0.23 per share, surpassing the Zacks Consensus Estimate of $0.16. This represents a positive surprise of 43.75% and a significant increase from $0.10 per share in the same quarter last year. Over the past four quarters, Aurinia has exceeded consensus earnings estimates three times, showcasing its strong financial performance.
Aurinia's revenue for the quarter ending September 2025 was $73.47 million, exceeding the Zacks Consensus Estimate by 7.31%. This marks an increase from $67.77 million in the same period last year. The company has consistently surpassed consensus revenue estimates in each of the last four quarters, highlighting its growth trajectory.
The stock price of AUPH has seen an increase of 8.35%, with a change of $1.10, currently priced at $14.27. The stock has fluctuated between a low of $13.50 and a high of $16.20 today, with $16.20 being its highest price over the past year. The lowest price for the stock in the past year was $6.55, indicating significant volatility.
AUPH has a market capitalization of approximately $1.88 billion, with a trading volume of 4,972,046 shares today. The company's recent financial performance and strategic direction, as discussed in the earnings call, have likely contributed to the stock's current valuation and market activity.
